Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout
Neurocrine Biosciences will acquire rare-disease drugmaker Soleno Therapeutics for $2.9 billion in cash, the companies said on Monday, marking the neuroscience-
April 06, 2026
3 family members assaulted Turning Point USA journalist at Minnesota protest, indictment says
Trial set for Overland Park man accused of stabbing captain on Hawaii snorkel tour
Kansas City man accused of high-speed chase in stolen SUV, fleeing into floodwater
Trump says that he's is weighing reducing American troop presence in Germany after Iran fued
Romanian man sentenced to 4 years in prison for swatting spree targeting dozens of US officials
Supreme Court ruling on race-based redistricting prompts quick action in some states
Wall Street ends mixed ahead of big tech earnings
Carvana's first-quarter profit rises on used-car demand
George Pickens signs $27.3 million franchise tag with Cowboys, opening door for offseason work